The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
Identifieur interne : 003E87 ( PubMed/Curation ); précédent : 003E86; suivant : 003E88The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.
Auteurs : H A Hana Asi [Turquie] ; G. Kaptanoglu ; H A Sahin ; M. EmreSource :
- Movement disorders : official journal of the Movement Disorder Society [ 0885-3185 ] ; 2000.
English descriptors
- KwdEn :
- Adult, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Dopamine Agents (administration & dosage), Dopamine Agents (therapeutic use), Dose-Response Relationship, Drug, Drug Therapy, Combination, Dyskinesia, Drug-Induced (etiology), Dyskinesia, Drug-Induced (prevention & control), Excitatory Amino Acid Antagonists (administration & dosage), Excitatory Amino Acid Antagonists (therapeutic use), Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Male, Memantine (administration & dosage), Memantine (therapeutic use), N-Methylaspartate (antagonists & inhibitors), Parkinsonian Disorders (complications), Parkinsonian Disorders (drug therapy), Treatment Outcome.
- MESH :
- chemical , administration & dosage : Dopamine Agents, Excitatory Amino Acid Antagonists, Memantine.
- chemical , antagonists & inhibitors : N-Methylaspartate.
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Dopamine Agents, Excitatory Amino Acid Antagonists, Levodopa, Memantine.
- complications : Parkinsonian Disorders.
- drug therapy : Parkinsonian Disorders.
- etiology : Dyskinesia, Drug-Induced.
- prevention & control : Dyskinesia, Drug-Induced.
- Adult, Dose-Response Relationship, Drug, Drug Therapy, Combination, Humans, Male, Treatment Outcome.
PubMed: 11009218
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003E87
Links to Exploration step
pubmed:11009218Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.</title>
<author><name sortKey="Hana Asi, H A" sort="Hana Asi, H A" uniqKey="Hana Asi H" first="H A" last="Hana Asi">H A Hana Asi</name>
<affiliation wicri:level="1"><nlm:affiliation>Istanbul University, Istanbul Medical Faculty, Department of Neurology, Capa, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Istanbul University, Istanbul Medical Faculty, Department of Neurology, Capa</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kaptanoglu, G" sort="Kaptanoglu, G" uniqKey="Kaptanoglu G" first="G" last="Kaptanoglu">G. Kaptanoglu</name>
</author>
<author><name sortKey="Sahin, H A" sort="Sahin, H A" uniqKey="Sahin H" first="H A" last="Sahin">H A Sahin</name>
</author>
<author><name sortKey="Emre, M" sort="Emre, M" uniqKey="Emre M" first="M" last="Emre">M. Emre</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2000">2000</date>
<idno type="RBID">pubmed:11009218</idno>
<idno type="pmid">11009218</idno>
<idno type="wicri:Area/PubMed/Corpus">003E87</idno>
<idno type="wicri:Area/PubMed/Curation">003E87</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.</title>
<author><name sortKey="Hana Asi, H A" sort="Hana Asi, H A" uniqKey="Hana Asi H" first="H A" last="Hana Asi">H A Hana Asi</name>
<affiliation wicri:level="1"><nlm:affiliation>Istanbul University, Istanbul Medical Faculty, Department of Neurology, Capa, Turkey.</nlm:affiliation>
<country xml:lang="fr">Turquie</country>
<wicri:regionArea>Istanbul University, Istanbul Medical Faculty, Department of Neurology, Capa</wicri:regionArea>
</affiliation>
</author>
<author><name sortKey="Kaptanoglu, G" sort="Kaptanoglu, G" uniqKey="Kaptanoglu G" first="G" last="Kaptanoglu">G. Kaptanoglu</name>
</author>
<author><name sortKey="Sahin, H A" sort="Sahin, H A" uniqKey="Sahin H" first="H A" last="Sahin">H A Sahin</name>
</author>
<author><name sortKey="Emre, M" sort="Emre, M" uniqKey="Emre M" first="M" last="Emre">M. Emre</name>
</author>
</analytic>
<series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2000" type="published">2000</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term>
<term>Antiparkinson Agents (pharmacology)</term>
<term>Antiparkinson Agents (therapeutic use)</term>
<term>Dopamine Agents (administration & dosage)</term>
<term>Dopamine Agents (therapeutic use)</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Therapy, Combination</term>
<term>Dyskinesia, Drug-Induced (etiology)</term>
<term>Dyskinesia, Drug-Induced (prevention & control)</term>
<term>Excitatory Amino Acid Antagonists (administration & dosage)</term>
<term>Excitatory Amino Acid Antagonists (therapeutic use)</term>
<term>Humans</term>
<term>Levodopa (pharmacology)</term>
<term>Levodopa (therapeutic use)</term>
<term>Male</term>
<term>Memantine (administration & dosage)</term>
<term>Memantine (therapeutic use)</term>
<term>N-Methylaspartate (antagonists & inhibitors)</term>
<term>Parkinsonian Disorders (complications)</term>
<term>Parkinsonian Disorders (drug therapy)</term>
<term>Treatment Outcome</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agents</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Memantine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="antagonists & inhibitors" xml:lang="en"><term>N-Methylaspartate</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Levodopa</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term>
<term>Dopamine Agents</term>
<term>Excitatory Amino Acid Antagonists</term>
<term>Levodopa</term>
<term>Memantine</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinsonian Disorders</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesia, Drug-Induced</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adult</term>
<term>Dose-Response Relationship, Drug</term>
<term>Drug Therapy, Combination</term>
<term>Humans</term>
<term>Male</term>
<term>Treatment Outcome</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">11009218</PMID>
<DateCreated><Year>2001</Year>
<Month>01</Month>
<Day>09</Day>
</DateCreated>
<DateCompleted><Year>2001</Year>
<Month>01</Month>
<Day>09</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0885-3185</ISSN>
<JournalIssue CitedMedium="Print"><Volume>15</Volume>
<Issue>5</Issue>
<PubDate><Year>2000</Year>
<Month>Sep</Month>
</PubDate>
</JournalIssue>
<Title>Movement disorders : official journal of the Movement Disorder Society</Title>
<ISOAbbreviation>Mov. Disord.</ISOAbbreviation>
</Journal>
<ArticleTitle>The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa.</ArticleTitle>
<Pagination><MedlinePgn>1016-7</MedlinePgn>
</Pagination>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hanağasi</LastName>
<ForeName>H A</ForeName>
<Initials>HA</Initials>
<AffiliationInfo><Affiliation>Istanbul University, Istanbul Medical Faculty, Department of Neurology, Capa, Turkey.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Kaptanoglu</LastName>
<ForeName>G</ForeName>
<Initials>G</Initials>
</Author>
<Author ValidYN="Y"><LastName>Sahin</LastName>
<ForeName>H A</ForeName>
<Initials>HA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Emre</LastName>
<ForeName>M</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D002363">Case Reports</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>UNITED STATES</Country>
<MedlineTA>Mov Disord</MedlineTA>
<NlmUniqueID>8610688</NlmUniqueID>
<ISSNLinking>0885-3185</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018691">Excitatory Amino Acid Antagonists</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>46627O600J</RegistryNumber>
<NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>6384-92-5</RegistryNumber>
<NameOfSubstance UI="D016202">N-Methylaspartate</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>W8O17SJF3T</RegistryNumber>
<NameOfSubstance UI="D008559">Memantine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N" UI="D000328">Adult</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D000978">Antiparkinson Agents</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D015259">Dopamine Agents</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004305">Dose-Response Relationship, Drug</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004359">Drug Therapy, Combination</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D004409">Dyskinesia, Drug-Induced</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000209">etiology</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000517">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D018691">Excitatory Amino Acid Antagonists</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D006801">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D007980">Levodopa</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000494">pharmacology</QualifierName>
<QualifierName MajorTopicYN="N" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008297">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D008559">Memantine</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000008">administration & dosage</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000627">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016202">N-Methylaspartate</DescriptorName>
<QualifierName MajorTopicYN="Y" UI="Q000037">antagonists & inhibitors</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D020734">Parkinsonian Disorders</DescriptorName>
<QualifierName MajorTopicYN="N" UI="Q000150">complications</QualifierName>
<QualifierName MajorTopicYN="Y" UI="Q000188">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName MajorTopicYN="N" UI="D016896">Treatment Outcome</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2000</Year>
<Month>9</Month>
<Day>29</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2001</Year>
<Month>2</Month>
<Day>28</Day>
<Hour>10</Hour>
<Minute>1</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2000</Year>
<Month>9</Month>
<Day>29</Day>
<Hour>11</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">11009218</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E87 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003E87 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= PubMed |étape= Curation |type= RBID |clé= pubmed:11009218 |texte= The use of NMDA antagonist memantine in drug-resistant dyskinesias resulting from L-dopa. }}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:11009218" \ | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \ | NlmPubMed2Wicri -a MovDisordV3
This area was generated with Dilib version V0.6.23. |